| 摘要 |
Disclosed are methods for the treatment of diseases or conditions of the eye with HPTP-beta inhibitors, especially retinopathies, ocular edema and ocular neovascularization. Non-limiting examples of these diseases or conditions include diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. Also disclosed are compositions comprising HPTP-beta inhibitors suitable for treating eye diseases and conditions. |
